Devonian Health Group Inc. (TSXV:GSD)
Canada
· Delayed Price · Currency is CAD | Market Cap | 36.51M |
| Revenue (ttm) | 23.59M |
| Net Income (ttm) | -6.01M |
| Shares Out | 165.94M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,500 |
| Average Volume | 21,097 |
| Open | 0.2200 |
| Previous Close | n/a |
| Day's Range | 0.2200 - 0.2200 |
| 52-Week Range | 0.0850 - 0.3500 |
| Beta | 1.06 |
| RSI | 57.18 |
| Earnings Date | Nov 28, 2025 |
About Devonian Health Group
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm... [Read more]
Financial Performance
In 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.
Financial StatementsNews
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
QUEBEC CITY — Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application for reinstatemen...
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
Statistically significant changes in fibrosis genes following three weeks of treatment with Thykamine™ Genes expression changes potentially expand the anti-fibrotic effects of Thykamine™ to fibrotic d...
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
QUEBEC CITY — Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announce...
Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study
In vitro study demonstrated superior potency of Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor Supports the clinical efficacy results of Thykamine™ in previous and ongoin...